Henning Willers: A randomized trial from China on primary lung cancer
Henning Willers, Director of the MGH Thoracic Radiation Oncology and Radiation Biology Program, shared a post on X about a paper by Hongfu Sun et al. published in the Journal of Clinical Oncology:
Authors: Hongfu Sun, Minghao Li, Wei Huang, Zicheng Zhang, Baosheng Li et al.
“Randomized trial out of China: Better PFS/OS for EGFR TKI + 60 Gy to primary lung cancer and LNs but also more toxicity
However:
- imbalance in prognostic factors favors radiotherapy group
- early separation of PFS curves suggests imbalance of prognostic factors
Am I wrong?”
Drew Moghanaki, Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology at UCLA, shared this post, adding:
“From my perspective, these data show that patients managed with TKI’s that aren’t working well can live longer with some vs no XRT. Whether the TKI is an older or newer generation.”
More posts featuring Henning Willers and Drew Moghanaki.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023